Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bmj.39490.680498.BE | DOI Listing |
J Med Virol
January 2025
Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 pandemic, has resulted in over 7 million confirmed deaths. In addition to severe respiratory and systematic symptoms, several comorbidities increase the risk of fatal outcomes. Therefore, it is essential to investigate the impact of COVID-19 on pre-existing conditions in patients, such as cancer and other infectious diseases.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2024
GSK, Rockville, USA.
This post-marketing surveillance study evaluated the safety of the adjuvanted recombinant zoster vaccine (RZV) in Chinese adults, given the limited country-specific safety data accumulated since the 2019 licensure of RZV in China for adults ≥ 50 years of age (YOA). This descriptive, prospective cohort study enrolled adults ≥ 50 YOA who voluntarily received RZV per routine clinical practice in six centers in China. The primary outcomes were occurrence, intensity, and causal relationship to vaccination of medically attended adverse events (MAEs) within 30 days post-any dose.
View Article and Find Full Text PDFCureus
November 2024
Department of Internal Medicine, Box Hill Hospital, Eastern Health, Melbourne, AUS.
Disseminated herpes zoster (DHZ), caused by the reactivation of latent varicella-zoster virus (VZV), is usually a condition that affects the immunocompromised population. It is uncommon in a vaccinated population. A previously well, independent 91-year-old lady with no known immunosuppressing conditions presented to the hospital with a productive cough and new confusion.
View Article and Find Full Text PDFBone Marrow Transplant
November 2024
Department of Medicine I/ Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Immunological reconstitution after allogeneic hematopoietic cell transplantation (alloHCT) is critical for patient survival. We compared short- and long-term immune reconstitution and clinical endpoints in adult recipients of haploidentical or mismatched T cell replete peripheral blood stem cell transplants (PBSCT) with post-transplant cyclophosphamide as GvHD prophylaxis (PTCY, n = 68) to: (a) patients receiving matched unrelated grafts and anti-T lymphocyte globulin (ATLG) (MUD/ATLG, n = 280); (b) patients with a mismatched donor and ATLG (MM/ATLG, n = 54); and (c) recipients of matched related grafts without ATLG (MRD/NoATLG, n = 97). PTCY was associated with delayed neutrophil engraftment, low NK-cell counts on day 30 and reduced CD8+ cells on days 60-80.
View Article and Find Full Text PDFFree Radic Biol Med
January 2025
Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361000, China; Xiamen Key Laboratory of Cardiovascular Diseases, Xiamen, Fujian, 361000, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!